直 Japanese PDF Font
  • Our Professionals
  • Our Work
  • Our Insights
  • Offices
  • Firm
  • Careers
Finnegan
  • Articles & Books
    • Ad Law Buzz Blog
    • At the PTAB Blog
    • European IP Blog
    • Federal Circuit IP Blog
    • INCONTESTABLE® Blog
    • Prosecution First Blog
  • Events & Webinars
  • IP Updates
  • Podcasts
    • AI + Finnegan
    • AI + Copyright
    • AI + Patent
    • AI + Privacy
    • AI + Trade Secrets
    • AI + Trademark
  • Unified Patent Court (UPC) Hub

At the PTAB Blog

Strict Limits on Claim Amendments During IPR

October 03, 2013

Authored and Edited by Arpita Bhattacharyya, Ph.D.; Jeffrey C. Totten

The patent statute permits a patent owner to file one motion to amend its claims after an IPR is instituted. In practice, however, the process is not so simple. At the recent IPO Annual Meeting in Boston, Lead Administrative Patent Judge, Hon. Michael Tierney, pointed to a decision in Idle Free Sys. Inc. v. Bergstrom. Inc. as an example of the Board’s approach to claim-amendment practice.

Under 37 C.F.R. § 42.121(a), a patent owner must confer with the Board before filing a motion to amend. Although the decision accepts that “it was not unreasonable for Bergstrom to have considered the initial conference call as satisfying the conferring requirement,” it nevertheless dismissed the patent owner’s motion to amend for failing to confer with the Board “about the specific amendments contemplated.”

The Board then provided extensive guidance for a proper motion to amend. The Board noted that § 42.121(a)(3) provides for a “reasonable number” of substitute claims, but with the express presumption that “only one substitute claim would be needed to replace each challenged claim.” Thus, "in the absence of special circumstance, a challenged claim can be replaced by only one claim.” Without clarifying what would constitute a “special circumstance,” the Board explained that “a desire to obtain a new set of claims having a hierarchy of different scope” would not suffice. The patent owner should also identify on a claim-by-claim basis the “contingency of substitution, e.g., which [substitute] claim for which [challenged] claim and in what circumstance.”

The Board also emphasized that IPR was not a permissible forum for broadening claim scope or remodeling claim structure according to a different strategy. 37 C.F.R. § 42.121(2)(i) only permits amendments responsive to grounds of unpatentability raised at trial, and a proposed substitute claim would not be responsive to an alleged ground of unpatentability if it “does not either include or narrow each feature of the challenged claim being replaced.” Moreover, because the patent owner bears the burden of demonstrating patentability of the proposed claims under 37 C.F.R. § 42.20(c), the patent owner should identify the feature(s) added to each substitute claim and explain how the proposed claims are patentable over both the prior art of record and any additional prior art known to the patent owner.

Thus, Idle Free highlights the limitations for amending claims during an IPR. As the Board suggested, patent owners may consider ex parte reexamination or reissue, perhaps concurrently with the IPR, to pursue claim amendments not permissible during IPR. 

Tags

claim amendments, motions to amend (MTA), substitute claims

Contacts

Jeffrey C. Totten
Partner
Washington, DC
+1 202 408 4232
Email

Copyright © 2013 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP. 

DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. Additional disclaimer information. 

Related Insights

Conference

7th International Conference on Biofuels and Bioenergy

June 25-26, 2026

Edinburgh

Conference

17th Summit on Biosimilars & Innovator Biologics

June 2-3, 2026

New York

At the PTAB Blog

Consistency Is Key – USPTO Issues Three New Informative Decisions

May 29, 2026

At the PTAB Blog

Discretion All the Way Down: USPTO Uses a Discretionary IPR Denial to Justify a    
§ 325(d) EPR Denial

May 28, 2026

Articles

Colorado Replaces Landmark AI Act: An Overview of the New SB 26-189 Framework

May 26, 2026

At the PTAB Blog

Claim Disclaimer Derails Instituted IPR in Freightcar America

May 26, 2026

At the PTAB Blog

IPR and PGR Statistics for Final Written Decisions Issued in March and April 2026

May 26, 2026

At the PTAB Blog

Before the Holding, the Message: Director Squires Uses Magnolia Medical to Outline PTAB Discretionary Denial Policy Changes

May 20, 2026

Conference

19th Annual Forum on Pharma & Biotech Patent Litigation in Europe

May 19-20, 2026

Amsterdam

Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.

  • Privacy
  • Disclaimer
  • Legal Notices
  • Fraud Alert
  • EEO Statement
  • Cookies
  • Contact Us

© 2026 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP